Published in Mol Cell on October 01, 2001
Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci U S A (2003) 3.26
Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest (2010) 2.44
The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) (2008) 2.30
ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal (2010) 1.91
Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol (2002) 1.60
The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J (2002) 1.55
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood (2011) 1.52
Monoubiquitinated Fanconi anemia D2 (FANCD2-Ub) is required for BCR-ABL1 kinase-induced leukemogenesis. Leukemia (2011) 1.43
RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res (2012) 1.36
DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol (2013) 1.30
DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia (2009) 1.24
Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution. Mol Cell Biol (2003) 1.23
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res (2009) 1.23
BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst) (2005) 1.23
Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A (2014) 1.22
BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia (2008) 1.21
Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol (2003) 1.21
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res (2008) 1.17
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood (2013) 1.16
Targeting DNA damage response in cancer therapy. Cancer Sci (2014) 1.16
Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci U S A (2008) 1.15
SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene (2012) 1.15
The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem (2010) 1.14
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood (2009) 1.13
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (2012) 1.12
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia (2010) 1.11
Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements. Genes Dev (2007) 1.10
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma (2008) 1.09
RAD51 haploinsufficiency causes congenital mirror movements in humans. Am J Hum Genet (2012) 1.04
Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer (2004) 1.04
Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. Radiother Oncol (2014) 1.03
An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem (2012) 0.98
Constitutive association of BRCA1 and c-Abl and its ATM-dependent disruption after irradiation. Mol Cell Biol (2002) 0.98
Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol (2011) 0.98
Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One (2011) 0.97
Evidence for a direct involvement of hMSH5 in promoting ionizing radiation induced apoptosis. Exp Cell Res (2009) 0.96
BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia (2008) 0.96
Rad51 regulates cell cycle progression by preserving G2/M transition in mouse embryonic stem cells. Stem Cells Dev (2014) 0.96
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med (2013) 0.95
DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange. Nucleic Acids Res (2009) 0.95
BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Res (2010) 0.94
Tyrosine phosphorylation enhances RAD52-mediated annealing by modulating its DNA binding. EMBO J (2011) 0.94
How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT (2013) 0.93
Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood (2011) 0.92
Biochemistry of eukaryotic homologous recombination. Top Curr Genet (2007) 0.91
Discriminatory suppression of homologous recombination by p53. Nucleic Acids Res (2004) 0.89
Increased RPA1 gene dosage affects genomic stability potentially contributing to 17p13.3 duplication syndrome. PLoS Genet (2011) 0.89
DNA polymerase beta overexpression stimulates the Rad51-dependent homologous recombination in mammalian cells. Nucleic Acids Res (2004) 0.89
Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors. J Cell Mol Med (2008) 0.87
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer (2004) 0.87
Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. Leuk Lymphoma (2011) 0.86
Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus. Ann Surg Oncol (2013) 0.86
Is homologous recombination really an error-free process? Front Genet (2014) 0.85
Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia. Blood Rev (2016) 0.84
BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability. Leukemia (2012) 0.84
MutS homologue hMSH5: recombinational DSB repair and non-synonymous polymorphic variants. PLoS One (2013) 0.81
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol (2008) 0.80
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. Mol Cancer Res (2015) 0.80
Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors. Eur J Med Chem (2015) 0.79
Tyrosine phosphorylation stimulates activity of human RAD51 recombinase through altered nucleoprotein filament dynamics. Proc Natl Acad Sci U S A (2016) 0.79
Regulation of Rad51 promoter. Cell Cycle (2014) 0.78
Multiple regulation of Rad51-mediated homologous recombination by fission yeast Fbh1. PLoS Genet (2014) 0.78
Role of the double-strand break repair pathway in the maintenance of genomic stability. Mol Cell Oncol (2014) 0.78
High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation. Cell Cycle (2015) 0.78
The Tumor-Associated Variant RAD51 G151D Induces a Hyper-Recombination Phenotype. PLoS Genet (2016) 0.77
The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors. Cancer Res (2014) 0.77
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clin Cancer Res (2016) 0.77
Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity. Blood Cancer J (2013) 0.77
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood (2016) 0.77
Synthetic lethality between gene defects affecting a single non-essential molecular pathway with reversible steps. PLoS Comput Biol (2013) 0.77
High RAD54B expression: an independent predictor of postoperative distant recurrence in colorectal cancer patients. Oncotarget (2015) 0.76
Against Lung Cancer Cells: To Be, or Not to Be, That Is the Problem. Lung Cancer Int (2012) 0.76
Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today (2015) 0.75
Overexpression of Rad51 Predicts Poor Prognosis in Colorectal Cancer: Our Experience with 54 Patients. PLoS One (2017) 0.75
Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone. PLoS One (2014) 0.75
DNA Repair-A Double-Edged Sword in the Genomic Stability of Cancer Cells-The Case of Chronic Myeloid Leukemia. Int J Mol Sci (2015) 0.75
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol (2011) 0.75
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest (2017) 0.75
BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell (2001) 6.75
Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res (1997) 4.61
hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A (1996) 3.60
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J (1997) 3.34
hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA. Mol Cell (1999) 2.85
The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. Cell (1997) 2.64
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Transcription from TATA-less promoters: dihydrofolate reductase as a model. Crit Rev Eukaryot Gene Expr (1993) 2.20
Interactions in the error-prone postreplication repair proteins hREV1, hREV3, and hREV7. J Biol Chem (2001) 2.19
A human REV7 homolog that interacts with the polymerase zeta catalytic subunit hREV3 and the spindle assembly checkpoint protein hMAD2. J Biol Chem (2000) 2.08
Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. J Exp Med (1998) 2.00
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem (1999) 1.96
Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut (2000) 1.95
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science (1991) 1.93
Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol (1991) 1.77
Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nat Genet (1997) 1.71
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood (1995) 1.69
Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A (1998) 1.62
DNA polymerase delta is required for human mismatch repair in vitro. J Biol Chem (1997) 1.61
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med (1999) 1.61
MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet (1999) 1.61
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res (2001) 1.60
TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J (1998) 1.60
Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) (2001) 1.59
Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res (1999) 1.58
Human exonuclease I interacts with the mismatch repair protein hMSH2. Cancer Res (1998) 1.53
The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer. J Biol Chem (1999) 1.48
Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst (1997) 1.47
Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest (1997) 1.44
The DNA damage response in DNA-dependent protein kinase-deficient SCID mouse cells: replication protein A hyperphosphorylation and p53 induction. Proc Natl Acad Sci U S A (1996) 1.44
De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A (1995) 1.43
Monoubiquitinated Fanconi anemia D2 (FANCD2-Ub) is required for BCR-ABL1 kinase-induced leukemogenesis. Leukemia (2011) 1.43
Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res (1997) 1.43
Severe attenuation of the B cell immune response in Msh2-deficient mice. J Exp Med (1999) 1.42
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol (1996) 1.42
The interaction of DNA mismatch repair proteins with human exonuclease I. J Biol Chem (2001) 1.42
Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene (1996) 1.42
Signaling mismatch repair in cancer. Nat Med (1999) 1.41
Nonhomologous recombination in human cells. Mol Cell Biol (1994) 1.40
The human homologous pairing protein HPP-1 is specifically stimulated by the cognate single-stranded binding protein hRP-A. Proc Natl Acad Sci U S A (1991) 1.39
Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci U S A (1999) 1.39
BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell (1998) 1.37
The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular switch. J Biol Chem (2000) 1.32
Mutator phenotype in Msh2-deficient murine embryonic fibroblasts. Cancer Res (1997) 1.31
Purification and characterization of a protein from human cells which promotes homologous pairing of DNA. J Biol Chem (1990) 1.28
Dissociation of mismatch recognition and ATPase activity by hMSH2-hMSH3. J Biol Chem (1999) 1.27
Interactions of human hMSH2 with hMSH3 and hMSH2 with hMSH6: examination of mutations found in hereditary nonpolyposis colorectal cancer. Mol Cell Biol (1998) 1.25
Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Mol Cell Biol (1995) 1.24
Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res (1998) 1.22
Oligonucleotide N3'-->P5' phosphoramidates as antisense agents. Nucleic Acids Res (1996) 1.22
BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia (2008) 1.21
Circular single-stranded RNA replicon in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1990) 1.21
hMSH5: a human MutS homologue that forms a novel heterodimer with hMSH4 and is expressed during spermatogenesis. Cancer Res (1999) 1.20
The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood (1998) 1.20
Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A (1994) 1.19
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc Natl Acad Sci U S A (1996) 1.15
Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med (1998) 1.13
Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res (2001) 1.12
Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene (2006) 1.12
Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood (1998) 1.11
Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers. Hum Pathol (2000) 1.09
BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci U S A (1998) 1.07
Differential cellular expression of the human MSH2 repair enzyme in small and large intestine. Cancer Res (1995) 1.07
Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res (1999) 1.06
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1994) 1.06
Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med (1994) 1.06
Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. J Biol Chem (1996) 1.03
Sequence analysis of the mismatch repair gene hMSH6 in the germline of patients with familial and sporadic colorectal cancer. Int J Cancer (2000) 1.02
Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene (2001) 1.01
BRCA1 and cell signaling. Oncogene (2000) 0.99
Characterization of the human homologue of RAD54: a gene located on chromosome 1p32 at a region of high loss of heterozygosity in breast tumors. Cancer Res (1997) 0.97
Human thymine-DNA glycosylase maps at chromosome 12q22-q24.1: a region of high loss of heterozygosity in gastric cancer. Cancer Res (1997) 0.97
C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res (1995) 0.96
Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br J Cancer (1997) 0.95
Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia (1994) 0.95
Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects. Biochim Biophys Acta (1999) 0.94
Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH). Cancer Res (1999) 0.92
Cocaine colitis. Is this a new syndrome? Dis Colon Rectum (1985) 0.91
Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in vivo. Proc Natl Acad Sci U S A (1997) 0.91
The effect of O6-methylguanine DNA adducts on the adenosine nucleotide switch functions of hMSH2-hMSH6 and hMSH2-hMSH3. J Biol Chem (2000) 0.91
Female embryonic lethality in Msh2-Trp53 nullizygous mice is strain dependent. Mamm Genome (1999) 0.89
Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J Exp Med (1995) 0.88
Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest (1993) 0.88
Cyclosporine A impairs wound healing in rats. J Surg Res (1983) 0.88
BCR/ABL regulation of PI-3 kinase activity. Leuk Lymphoma (1996) 0.85
CD4+/CD25+ cells in systemic inflammation in COPD. Scand J Immunol (2011) 0.84
Cell cycle regulation of the human DNA mismatch repair genes hMSH2, hMLH1, and hPMS2. Cancer Res (1997) 0.84
BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability. Leukemia (2012) 0.84
A mutant HpaII methyltransferase functions as a mutator enzyme. Nucleic Acids Res (1995) 0.84